Prostaglandins and Other Lipid Mediators This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Physiological and pathological levels of Prostaglandin E2 in renal parenchyma and neoplastic renal tissue
Publication date: Available online 10 February 2019Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Vittore Verratti, Luigi Brunetti, Claudio Ferrante, Giustino Orlando, Lucia Recinella, Annalisa Chiavaroli, Sheila Leone, Run Wang, Francesco BerardinelliAbstractProstaglandin (PG)E2 seems to promote tumor proliferation by regulating cell growth, inhibiting apoptosis, promoting angiogenesis, and suppressing host immune surveillance of cancer cells. The suppression of prostaglandins biosynthesis is thought to be the main molecular mechanism for non-steroidal anti-inflammatory drugs antineoplastic effect. Yet the relat...
Source: Prostaglandins and Other Lipid Mediators - February 11, 2019 Category: Lipidology Source Type: research

Leukotriene B4 modulation of murine dendritic cells affects adaptive immunity
Publication date: Available online 8 February 2019Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Marco Antonio Pires-Lapa, Marianna Mainardi Koga, Ildefonso Alves da Silva-, Luciano Ribeiro Filgueiras, Sonia JancarAbstractDendritic cells (DCs) link innate and adaptive immunity. The microenvironment generated during the innate immunity affects DCs and the type of adaptive immunity generated. Lipid mediators are released early in inflammation and could modify the functional state of DCs. Leukotriene B4 (LTB4) has a wide range of effects on macrophages and in the present study we investigated if it also affects DCs....
Source: Prostaglandins and Other Lipid Mediators - February 8, 2019 Category: Lipidology Source Type: research

Upregulation of cystathionine-γ-lyase/hydrogen sulfide pathway underlies the celecoxib counteraction of cyclosporine-induced hypertension and renal insult in rats
Publication date: Available online 15 January 2019Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Mai M. Helmy, Maged W. Helmy, Mahmoud M. El-MasAbstractWe recently reported that celecoxib, a selective cyclooxygenase-2 (COX2) inhibitor, counteracts the adverse circulatory and renal actions of cyclosporine (CSA). Despite the seemingly advantageous nature of this interaction particularly in clinical settings that necessitate the combined use of the two drugs such as immune-related arthritis, the underlying mechanism remains elusive. This prompted us to test the hypothesis that the facilitation of the cystathionine-Î...
Source: Prostaglandins and Other Lipid Mediators - January 16, 2019 Category: Lipidology Source Type: research

Editorial Board
Publication date: February 2019Source: Prostaglandins & Other Lipid Mediators, Volume 140Author(s): (Source: Prostaglandins and Other Lipid Mediators)
Source: Prostaglandins and Other Lipid Mediators - January 9, 2019 Category: Lipidology Source Type: research

Development of Multitarget Agents Possessing Soluble Epoxide Hydrolase Inhibitory Activity
Publication date: Available online 26 December 2018Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Kerstin Hiesinger, Karen M. Wagner, Bruce D. Hammock, Ewgenij Proschak, Sung Hee HwangABSTRACTOver the last two decades polypharmacology has emerged as a new paradigm in drug discovery, even though developing drugs with high potency and selectivity toward a single biological target is still a major strategy. Often, targeting only a single enzyme or receptor shows lack of efficacy. High levels of inhibitor of a single target also can lead to adverse side effects. A second target may offer additive or synergistic effec...
Source: Prostaglandins and Other Lipid Mediators - December 27, 2018 Category: Lipidology Source Type: research

Inhibition of ASM activity ameliorates DSS-induced colitis in mice
Publication date: Available online 11 December 2018Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Yan Xiong, Xiao-Dan Zhu, Ping Wan, Yu-Ping Ren, Chong Wang, Run-Wei Yan, Yuan Guo, Ai-Ping BaiAbstractAcid sphingomyelinase (ASM) is a membrane lipid hydrolase, acting to generate ceramide and regulate cell functions and inflammatory responses.The roles of ASM in mediating T cell functions are postulated whereas its function in regulation of macrophages remains uncertain. The study was performed to explore ASM activity in control of macrophage functions. RAW 264.7 cells were pretreated with desipramine, an ASM inhibi...
Source: Prostaglandins and Other Lipid Mediators - December 12, 2018 Category: Lipidology Source Type: research

VIP Modulates the ALX/FPR2 Receptor Axis toward Inflammation Resolution in a Mouse Model of Bacterial Keratitis
Publication date: Available online 4 December 2018Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Thomas W. Carion, David Kracht, Eliisa Strand, Edwin David, Cody McWhirter, Abdul Shukkur Ebrahim, Elizabeth A BergerAbstractVasoactive intestinal peptide (VIP) has been shown to regulate corneal inflammation. Formyl peptide receptor 2 (FPR2) is a transmembrane protein belonging to the GPCR family. Ligands include pro-resolving lipids, lipoxin A4 (LXA4) and resolvin D1 (RvD1). The current study focuses on the effect of VIP regarding the FPR2 receptor axis in improving disease outcome in a mouse model of bacterial kera...
Source: Prostaglandins and Other Lipid Mediators - December 5, 2018 Category: Lipidology Source Type: research

Detoxification and activating blood circulation decoction reduces restenosis involving the TLR4/NF-κB pathway after balloon injury
Publication date: Available online 16 November 2018Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Guohui Zou, Jinhua Zhu, Zhongyong Liu, Lu Wu, Ri Xu, Hongtao Chen, Peng Deng, Changqing DengAbstractRestenosis is a major problem after percutaneous coronary intervention (PCI) treatment. Inflammation is one of the major core mechanisms involved in the occurrence of restenosis, and plays an important role in intimal hyperplasia. Detoxification and activating blood circulation decoction (DABCD) is a traditional Chinese medicine that is used in the treatment and prevention of atherosclerotic and inflammatory diseases. ...
Source: Prostaglandins and Other Lipid Mediators - November 17, 2018 Category: Lipidology Source Type: research

Editorial Board
Publication date: November 2018Source: Prostaglandins & Other Lipid Mediators, Volume 139Author(s): (Source: Prostaglandins and Other Lipid Mediators)
Source: Prostaglandins and Other Lipid Mediators - November 16, 2018 Category: Lipidology Source Type: research

BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system
ConclusionBML-111 could protect against acute injury via regulation RAAS. (Source: Prostaglandins and Other Lipid Mediators)
Source: Prostaglandins and Other Lipid Mediators - November 8, 2018 Category: Lipidology Source Type: research

Variability in Analgesic Response to Non-Steroidal Anti-Inflammatory Drugs
Publication date: Available online 25 October 2018Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Katherine N. ThekenAbstractNonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used agents for the treatment of acute and chronic pain. However, it has long been recognized that there is substantial inter-individual variability in the analgesic response to NSAIDs, reflecting the complex interplay between mechanisms of pain, differences between distinct NSAIDs, and patient-specific factors such as genetic variation. This review summarizes the current knowledge regarding how these factors contribut...
Source: Prostaglandins and Other Lipid Mediators - October 26, 2018 Category: Lipidology Source Type: research

Comparison of pro-adipogenic effects between prostaglandin (PG) D2 and its stable, isosteric analogue, 11-deoxy-11-methylene-PGD2, during the maturation phase of cultured adipocytes
Publication date: Available online 26 October 2018Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Mohammad Shahidur Rahman, Pinky Karim Syeda, Michael N.N. Nartey, Md. Mazharul Islam Chowdhury, Hidehisa Shimizu, Kohji Nishimura, Mitsuo Jisaka, Fumiaki Shono, Kazushige YokotaAbstractProstaglandin (PG) D2 is relatively unstable and dehydrated non-enzymatically into PGJ2 derivatives, which are known to serve as pro-adipogenic factors by activating peroxisome proliferator-activated receptor (PPAR) γ, a master regulator of adipogenesis. 11-Deoxy-11-methylene-PGD2 (11d-11m-PGD2) is a novel, chemically stable, isosteric...
Source: Prostaglandins and Other Lipid Mediators - October 26, 2018 Category: Lipidology Source Type: research

Apolipoprotein A-IV: a potential therapeutic target for atherosclerosis
This article focus on current studies and the possible anti-atherogenic mechanism related to apoA-IV, in order to provide a new therapeutic target for atherosclerotic cardiovascular diseases. (Source: Prostaglandins and Other Lipid Mediators)
Source: Prostaglandins and Other Lipid Mediators - October 23, 2018 Category: Lipidology Source Type: research

Role of dyslipidemia in preeclampsia—A review of lipidomic analysis of blood, placenta, syncytiotrophoblast microvesicles and umbilical cord artery from women with preeclampsia
Publication date: November 2018Source: Prostaglandins & Other Lipid Mediators, Volume 139Author(s): Daniela Wojcik-Baszko, Karol Charkiewicz, Piotr LaudanskiAbstractPreeclampsia is a complex disorder and the pathogenesis of it is still not fully understood. The most commonly accepted theory of pathogenesis assumes that there occurs impaired trophoblastic invasion and failure in spiral artery remodeling. Nowadays, obesity becomes one of the most important, modifiable risk factors for the development of preeclampsia. Despite research into the condition, predicting which women with risk factors will develop preeclampsia remai...
Source: Prostaglandins and Other Lipid Mediators - October 9, 2018 Category: Lipidology Source Type: research

Isolevuglandins and Cardiovascular Disease
Publication date: Available online 5 October 2018Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Sean S Davies, Linda S. May-ZhangAbstractIsolevuglandins are 4-ketoaldehydes formed by peroxidation of arachidonic acid. Isolevuglandins react rapidly with primary amines including the lysyl residues of proteins to form irreversible covalent modifications. This review highlights evidence for the potential role of isolevuglandin modification in the disease processes, especially atherosclerosis, and some of the tools including small molecule dicarbonyl scavengers utilized to assess their contributions to disease. (Source...
Source: Prostaglandins and Other Lipid Mediators - October 6, 2018 Category: Lipidology Source Type: research